Evidence map›Paper›PMID 40999474›Full record

ArticleGut pathogens2025

Analysis of antimicrobial resistance patterns and genetic mutations in Helicobacter pylori from West Bengal, India depicting escalating clarithromycin and high levofloxacin resistance.

Sangita Paul, Bipul Chandra Karmakar, Nirupam Roy, Sujit Chaudhuri, Asish Kumar Mukhopadhyay

Abstract read
In one paragraph

Article in Gut pathogens, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Association of Resistance-AssociatedAntibiotics (Basel, Switzerland) · 2026
    Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Sangita PaulDivision of Bacteriology, ICMR-National Institute of Cholera and Enteric Diseases ICMR-NICED), P-33, CIT Rd, Subhas Sarobar Park, Phool Bagan, Beliaghata, Kolkata, 700010, India.
Bipul Chandra KarmakarDivision of Bacteriology, ICMR-National Institute of Cholera and Enteric Diseases ICMR-NICED), P-33, CIT Rd, Subhas Sarobar Park, Phool Bagan, Beliaghata, Kolkata, 700010, India.
Nirupam RoyDivision of Bacteriology, ICMR-National Institute of Cholera and Enteric Diseases ICMR-NICED), P-33, CIT Rd, Subhas Sarobar Park, Phool Bagan, Beliaghata, Kolkata, 700010, India.
Sujit ChaudhuriManipal Hospitals Broadway (Formerly AMRI Hospital Salt Lake), Kolkata, 700106, India.
Asish Kumar MukhopadhyayDivision of Bacteriology, ICMR-National Institute of Cholera and Enteric Diseases ICMR-NICED), P-33, CIT Rd, Subhas Sarobar Park, Phool Bagan, Beliaghata, Kolkata, 700010, India. asish_mukhopadhyay@yahoo.com.

Funding

Council of Scientific and Industrial Research, India 09/482(0065)/2017-EMR-IDepartment of Science and Technology, Ministry of Science and Technology, India DST/INSPIRE Fellowship/2014/IF140909Indian Council of Medical Research 5/3/8/36/ITR-F/2020University Grants Commission 201610173886
6 · The paper itself

Abstract

backgroundThe growing resistance of Helicobacter pylori (H. pylori) to antibiotics poses a significant global health challenge, particularly in developing regions where infection rates are high, and routine antibiotic susceptibility surveillance is limited. This study aimed to evaluate the antimicrobial resistance patterns and associated genetic mutations in H. pylori strains isolated from patients in West Bengal (WB), India.

methodsA total of 88 H. pylori strains were isolated from gastric biopsy samples collected between 2018 and 2020 from patients diagnosed with gastritis, duodenal ulcer, or gastric cancer. Antimicrobial susceptibility was determined using the agar dilution method against six antibiotics: metronidazole, tetracycline, clarithromycin, furazolidone, levofloxacin, and amoxicillin. Resistance-associated mutations in gyrA (levofloxacin), frxA and rdxA (metronidazole), and pbp1A (amoxicillin) were characterized via Sanger sequencing. Mutations in the 23SrRNA gene, implicated in clarithromycin resistance, were identified through allele-specific PCR, validated by Sanger sequencing and transformation assays. Additionally, BsaI and BbsI restriction enzyme digestion was used to confirm specific point mutations in 23SrRNA gene of clarithromycin-resistant isolates.

resultsOf 210 biopsies analyzed, 79 (37.6%) were H. pylori-positive, yielding 88 distinct strains-some patients harbored multiple genetically diverse isolates, identified by differences in cagA/vacA genotypes and antibiotic resistance profiles. Although, no association was found between virulence gene profile and resistance pattern. Resistance rates were highest for levofloxacin (69.3%), followed by metronidazole (61.4%) and clarithromycin (19.3%). Nearly all clarithromycin-resistant isolates carried the A2143G mutation in the 23SrRNA gene, capable of getting naturally transmitted into the next generations also. Levofloxacin-resistant strains harbored mutations in GyrA at codons 63, 87, 88, 91, 130, and 150, and a novel Gly85Ala substitution was identified. Metronidazole resistance correlated more strongly with rdxA mutations than with frxA. No resistance was detected against furazolidone and tetracycline, while amoxicillin resistance was rare (1.1%). Multidrug resistance was observed in 10.2% of isolates, with 32.9% displaying dual resistance to metronidazole + levofloxacin, and 6.8% to clarithromycin + levofloxacin.

conclusionsHigh clarithromycin, substantial metronidazole and levofloxacin resistance in H. pylori strains from WB underscore the urgent need to revise empirical treatment strategies. These findings advocate for localized, resistance-guided therapy protocols and reinforce the importance of continuous antimicrobial surveillance to optimize treatment outcomes and mitigate resistance development.

Indexed as

Antimicrobial resistancecagA and vacAclarithromycin resistanceHelicobacter pyloriMinimum inhibitory concentrationMultidrug resistance

Identifiers

PMID40999474
PMCPMC12465208

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.